Improving Alpha-Emitter Therapy for Neuroendocrine Tumors and Protecting Kidneys
Official title: Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
Funded at Research Inst Nationwide Children's Hosp · NIH-11115687 · Data updated 2026-11-12
This project looks for better ways to treat neuroendocrine tumors with a special type of radiation therapy, while also keeping kidneys safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $599,573 |
| NIH project number | 5R01CA291827-02 |
| Project ID | NIH-11115687 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with neuroendocrine tumors that express the SSTR2 receptor, who might be candidates for alpha-emitter radioligand therapy, could potentially benefit from this research.
✕Less likely to help
Patients with tumor types that do not express the SSTR2 receptor or those who are not candidates for radioligand therapy may not directly benefit from this specific approach.
What this research studies
We are working to make a powerful new radiation treatment for neuroendocrine tumors even safer and more effective. This therapy uses alpha-emitters, which have shown great promise in shrinking tumors, but can sometimes affect the kidneys. Our goal is to find the best treatment plan, including the right dose and timing, and to use special medicines that protect the kidneys. We will also use new urine tests to quickly spot any kidney changes, ensuring patients receive the most benefit with the fewest side effects.
Why it matters
Potential benefit: If successful, this work could lead to more effective and safer alpha-emitter radioligand therapy for patients with neuroendocrine tumors, reducing the risk of kidney damage.
How similar studies have gone: Alpha-emitter radioligand therapies have shown promising tumor response rates in early clinical studies, but this project introduces novel strategies for kidney protection and optimized dosing.
Where this research is happening
-
Research Inst Nationwide Children's Hosp
Columbus, United States Active
Researchers
- Principal investigator: Zepeda-Orozco, Diana — Research Inst Nationwide Children's Hosp
- Study coordinator: Zepeda-Orozco, Diana
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.